Trials / Terminated
TerminatedNCT04808570
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3525 tablets | TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle. |
Timeline
- Start date
- 2021-06-05
- Primary completion
- 2023-11-22
- Completion
- 2023-11-22
- First posted
- 2021-03-22
- Last updated
- 2023-11-29
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04808570. Inclusion in this directory is not an endorsement.